Gilead Sciences, Inc. (GILD)
Pre-Market:
| Previous Close | 84.67 |
| Open | 84.86 |
| Bid | 84.90 x 400 |
| Ask | 84.96 x 100 |
| Day's Range | 84.17 - 84.97 |
| 52 Week Range | 62.07 - 87.87 |
| Volume | |
| Avg. Volume | 6,444,339 |
| Market Cap | 105.762B |
| Beta (5Y Monthly) | 0.20 |
| PE Ratio (TTM) | 103.60 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.08 (3.63%) |
| Ex-Dividend Date | Sept 13, 2024 |
| 1y Target Est | N/A |
- Business Wire
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2024 financial results and guidance will be released on Wednesday, November 6, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2024 financial results and provide a business update.
- Business Wire
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
FOSTER CITY, Calif., October 09, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek 2024, taking place from October 16-19. The data from 31 presentations across HIV treatment and prevention, COVID-19 and viral hepatitis include one late breaker abstract and six oral presentations, reflecting Gilead’s commitment to helping address the evolving needs of a diverse range of people and com
- Business Wire
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.
